Table 5.

Change in best-corrected visual acuity (based on standard letters) at each visit by treatment group.

Change from Baseline within Treatment Group*
Estimate (95% Confidence interval) P-value
	Periocular		Intravitreal		Dexamethasone
Week 4	2.78 (0.20, 5.36)	0.034	10.14 (7.59, 12.69)	<0.0001	7.28 (4.45, 10.10)	<0.0001
Week 8	4.37 (1.86, 6.89)	0.0007	9.70 (7.26, 12.13)	<0.0001	9.53 (7.01, 12.05)	<0.0001
Week 12	4.67 (2.14, 7.21)	0.0003	10.43 (7.67, 13.18)	<0.0001	7.24 (4.34, 10.14)	<0.0001
Week 20	5.17 (1.89, 8.46)	0.002	9.88 (6.72, 13.04)	<0.0001	7.67 (5.23, 10.11)	<0.0001
Week 24	4.07 (0.64, 7.51)	0.020	9.60 (6.87, 12.34)	<0.0001	9.21 (6.62, 11.80)	<0.0001
Difference in Change from Baseline between Treatment Groups*
Estimate (95% Confidence interval) P-value
	Intravitreal - Periocular		Dexamethasone - Periocular		Dexamethasone Intravitreal
Week 4	7.36 (3.74, 10.98)	<0.0001	4.49 (0.67, 8.31)	0.021	−2.86 (−6.66, 0.94)	0.14
Week 8	5.32 (1.82, 8.82)	0.003	5.16 (1.60, 8.72)	0.004	ࢤ0.16 (−3.67, 3.34)	0.93
Week 12	5.75 (2.01, 9.49)	0.003	2.57 (−1.28, 6.42)	0.19	ࢤ3.19 (−7.19, 0.81)	0.12
Week 20	4.71 (0.16, 9.26)	0.042	2.50 (−1.59, 6.58)	0.23	ࢤ2.21 (−6.20, 1.78)	0.28
Week 24	5.53 (1.14, 9.92)	0.013	5.14 (0.84, 9.44)	0.019	ࢤ0.40 (−4.16, 3.37)	0.84

^*An improvement of 15 letters (3 lines) corresponds to halving of the visual angle.